Cargando…

Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review

BACKGROUND: Progression-free survival (PFS) is a surrogate endpoint widely used for overall survival (OS) in oncology. Validation of PFS as a surrogate must be done for each indication and each intervention. We aimed to identify all studies evaluating the validity of PFS as a surrogate for OS in onc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belin, Lisa, Tan, Aidan, De Rycke, Yann, Dechartres, Agnès
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250908/ https://www.ncbi.nlm.nih.gov/pubmed/32214230 http://dx.doi.org/10.1038/s41416-020-0805-y

Ejemplares similares

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
por: Hess, Lisa M, et al.
Publicado: (2019)

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
por: Zhang, Zewei, et al.
Publicado: (2023)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
por: Forsythe, Anna, et al.
Publicado: (2018)

Quantifying the association between progression‐free survival and overall survival in oncology trials using Kendall's τ
por: Weber, Enya M., et al.
Publicado: (2018)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
por: Han, Kelong, et al.
Publicado: (2014)

Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma
por: Jiménez‐Ubieto, Ana, et al.
Publicado: (2017)

A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
por: Cooper, Katy, et al.
Publicado: (2020)

Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yin, et al.
Publicado: (2022)

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
por: Paoletti, Xavier, et al.
Publicado: (2020)

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis
por: Yang, Yin, et al.
Publicado: (2022)

Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
por: Han, Weiming, et al.
Publicado: (2022)

A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer
por: Gyawali, Bishal, et al.
Publicado: (2021)

Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review
por: Araujo, Raphael L C, et al.
Publicado: (2017)

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists
por: Methy, Nicolas, et al.
Publicado: (2010)

Progression-free or overall survival…revisited in BOLERO-2
por: Gupta, Sudeep
Publicado: (2014)

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors
por: Chowdhury, Simon, et al.
Publicado: (2020)

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
por: Nie, Run-Cong, et al.
Publicado: (2020)

Progression‐free survival at 3 years is a reliable surrogate for 5‐year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma
por: Yang, Yu‐Xian, et al.
Publicado: (2022)

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
por: Wang, Xiaofei, et al.
Publicado: (2017)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
por: Maeda, Hideki, et al.
Publicado: (2021)

Prognostic Factors of Atypical Meningioma: Overall Survival Rate and Progression Free Survival Rate
por: Lee, Jae Ho, et al.
Publicado: (2017)

Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan
por: Okabe, Ayano, et al.
Publicado: (2023)

Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
por: Zhu, Guang‐Li, et al.
Publicado: (2021)

Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lux, Michael Patrick, et al.
Publicado: (2019)

Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis
por: Ghali, Fady, et al.
Publicado: (2022)

Survival of surrogate coronaviruses in water
por: Casanova, Lisa, et al.
Publicado: (2009)

Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review
por: Zhu, Jie, et al.
Publicado: (2020)

Prognostic factors for progression‐free and overall survival in malignant pleural mesothelioma
por: Guzmán‐Casta, Jordi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g6ci59tde8dqdkbgfqpvdn0g5l